Iovance raises 2026 revenue guidance to $410 million-$420 million
AI Summary- Iovance raised its full-year 2026 total revenue guidance after reporting sustained demand for Amtagvi.
- Guidance increased to $410 million-$420 million from a previous $350 million-$370 million range.
- Iovance expanded its Authorized Treatment Center network to approximately 100 locations through the third quarter.